Epidemiology and Health Care of Generalized Pustular Psoriasis in Germany - Methodology and Outcomes of Claims Data Analysis.

IF 5.2 Q1 DERMATOLOGY
Psoriasis (Auckland, N.Z.) Pub Date : 2025-07-15 eCollection Date: 2025-01-01 DOI:10.2147/PTT.S529515
Kristina Hagenström, Katharina Müller, Nesrine Ben-Anaya, Matthias Augustin
{"title":"Epidemiology and Health Care of Generalized Pustular Psoriasis in Germany - Methodology and Outcomes of Claims Data Analysis.","authors":"Kristina Hagenström, Katharina Müller, Nesrine Ben-Anaya, Matthias Augustin","doi":"10.2147/PTT.S529515","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>Epidemiological and health care data on generalized pustular psoriasis (GPP) show large differences in literature. This study assessed GPP epidemiology, comorbidities and health care in Germany.</p><p><strong>Patients and methods: </strong>Nationwide population-related German claims data were analyzed using different case definitions for internal validation.</p><p><strong>Results: </strong>In 2019, the prevalence of GPP in Germany in adults ranged from 8 to 39 and incidence from 1 to 15 persons per 100,000. Prevalence was higher in women and increased with age. Thirty-three percent had at least one other psoriatic ICD-10 code. People with GPP had significantly more skin diseases as well as cardiovascular and mental diseases than persons without psoriasis/GPP. The average annual drug costs per capita were € 2050 and were highest in those receiving biologicals (€ 15,524). Marked differences in treatment by specialist were observed.</p><p><strong>Conclusion: </strong>Acknowledging that the observed frequency or costs associated with GPP may be underestimated due to a few inherent limitations is important. Differences in GPP coding behavior and diagnostic accuracy may contribute to variations in epidemiology. The high disease burden is reflected by high annual costs and by significant comorbidity.</p>","PeriodicalId":74589,"journal":{"name":"Psoriasis (Auckland, N.Z.)","volume":"15 ","pages":"273-283"},"PeriodicalIF":5.2000,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12275989/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Psoriasis (Auckland, N.Z.)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2147/PTT.S529515","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"DERMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose: Epidemiological and health care data on generalized pustular psoriasis (GPP) show large differences in literature. This study assessed GPP epidemiology, comorbidities and health care in Germany.

Patients and methods: Nationwide population-related German claims data were analyzed using different case definitions for internal validation.

Results: In 2019, the prevalence of GPP in Germany in adults ranged from 8 to 39 and incidence from 1 to 15 persons per 100,000. Prevalence was higher in women and increased with age. Thirty-three percent had at least one other psoriatic ICD-10 code. People with GPP had significantly more skin diseases as well as cardiovascular and mental diseases than persons without psoriasis/GPP. The average annual drug costs per capita were € 2050 and were highest in those receiving biologicals (€ 15,524). Marked differences in treatment by specialist were observed.

Conclusion: Acknowledging that the observed frequency or costs associated with GPP may be underestimated due to a few inherent limitations is important. Differences in GPP coding behavior and diagnostic accuracy may contribute to variations in epidemiology. The high disease burden is reflected by high annual costs and by significant comorbidity.

德国广泛性脓疱性牛皮癣的流行病学和卫生保健——索赔数据分析的方法和结果。
目的:广泛性脓疱性银屑病(GPP)的流行病学和卫生保健资料在文献中存在较大差异。本研究评估了德国GPP的流行病学、合并症和卫生保健。患者和方法:使用不同的病例定义对德国全国人口相关索赔数据进行分析,以进行内部验证。结果:2019年,德国成人GPP患病率为8至39人,发病率为每10万人1至15人。女性患病率较高,且随年龄增长而增加。33%的人至少有一个其他的银屑病ICD-10代码。与没有银屑病/GPP的人相比,患有GPP的人有更多的皮肤疾病、心血管疾病和精神疾病。人均年平均药品费用为2050欧元,接受生物制剂的人均药品费用最高(15,524欧元)。观察到专家治疗的显著差异。结论:认识到由于一些固有的限制,与GPP相关的观察频率或成本可能被低估是很重要的。GPP编码行为和诊断准确性的差异可能导致流行病学的差异。高的疾病负担反映在高的年度费用和显著的合并症上。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
审稿时长
16 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信